Business Standard

Wednesday, December 25, 2024 | 12:50 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Glenmark Pharma jumps 5% post December quarter earnings

The company reported a 21 per cent surge in Q3 consolidated net at Rs 291 crore.

glenmark
Premium

glenmark

SI Reporter Mumbai
Shares of Glenmark Pharma surged over 5 per cent to a high of Rs 421 in an otherwise sluggish market, after the drug maker reported steady earnings for the quarter ended December 2022.

Glenmark reported a 21.1 per cent jump in Q3FY22 consolidated net to Rs 290.76 crore as against Rs 240 crore in the corresponding quarter a year ago. Net sales grew by 8 per cent YoY to Rs 3,392.24 crore.

During the third quarter, revenues from the Asia, MEA, LATAM and RCIS (RoW) region were Rs 654.1 crore as against Rs 534.8 crore for the previous corresponding quarter. Sales from

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in